Drug Trial News

RSS

Metabolex announces positive results from phase 2 trial of MBX-8025

The Phase 2 study was a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of MBX-8025, both alone and in combination with atorvastatin (marketed as Lipitor(R)), over an 8-week treatment period.

19 Nov 2008

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine.

19 Nov 2008

KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.

19 Nov 2008

Gentium S.p.A. updates on phase 3 trial of Defibrotide for severe veno-occlusive disease

Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).

19 Nov 2008

REOLYSIN shown to benefit some sarcoma patients

New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives.

19 Nov 2008

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

19 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

NCI sponsors Canadian cold/flu remedy trial in leukemia patients

Cancer patients, with their weakened immune systems, are particularly vulnerable when the cold and flu season hits. The National Cancer Institute (NCI), part of the National Institutes of Health and the world's most prestigious cancer research body, is sponsoring a landmark trial to evaluate if a unique Canadian cold remedy - ginseng extract COLD-FX - can help.

18 Nov 2008

Maas Biolab scientists validate cyclosporin human neuroprotection

Maas Biolab researchers CSO Eskil Elmer, M.D., Ph.D. and neuroscientist Magnus Hansson, M.D., Ph.D., and colleagues have for the first time ever demonstrated the mitochondrial permeability transition (mPT) or "megapore" occurs in viable adult human neuron mitochondria and the ability of cyclosporin-A to block its formation.

18 Nov 2008

Study looks at investigational compound MK-677 in Alzheimer's disease

A new study shows that a drug that increases the release of growth hormone failed to slow the rate of progression of Alzheimer's disease in humans.

17 Nov 2008

COLD-FX remedy undergoes NCI-sponsored trial in leukemia patients

Cancer patients - with their weakened immune systems - are particularly vulnerable when the cold and flu season hits.

17 Nov 2008

CAPHOSOL shown to benefit cancer patients undergoing chemotherapy and radiation therapy

New data show that CAPHOSOL, an advanced electrolyte solution, results in low rates of oral mucositis and pain in patients with head and neck (HN) cancer who are undergoing chemotherapy and radiation therapy.

17 Nov 2008

Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment

The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.

16 Nov 2008

Vigabatrin offers hope for treating relapse to methamphetamine abuse

A new study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) blocks drug-seeking behavior in animals previously trained to associate methamphetamine with a particular environment.

16 Nov 2008

Genetic Immunity announces first patient dosed in trial with DermaVir patch for HIV

Genetic Immunity, a US/Hungarian clinical-stage company focused on development of nanomedicines for targeted immune amplification, today announced it has treated the first subject in a Phase II clinical study to evaluate DermaVir Patch.

13 Nov 2008

Rosuvastatin trial shows dramatic reduction in hidden heart disease

A Harvard-led study shows that the risk of heart attack and stroke among subjects with "silent heart disease" - and normal cholesterol levels - can be dramatically reduced by the use of an already widely prescribed class of drugs.

13 Nov 2008

Phosphagenics' diclofenac enters trial phase in humans

Phosphagenics Limited ("Phosphagenics") announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.

12 Nov 2008

Drug Trial News

Metabolex announces positive results from phase 2 trial of MBX-8025

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

Gentium S.p.A. updates on phase 3 trial of Defibrotide for severe veno-occlusive disease

REOLYSIN shown to benefit some sarcoma patients

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

NCI sponsors Canadian cold/flu remedy trial in leukemia patients

Maas Biolab scientists validate cyclosporin human neuroprotection

Study looks at investigational compound MK-677 in Alzheimer's disease

COLD-FX remedy undergoes NCI-sponsored trial in leukemia patients

CAPHOSOL shown to benefit cancer patients undergoing chemotherapy and radiation therapy

Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment

Vigabatrin offers hope for treating relapse to methamphetamine abuse

Genetic Immunity announces first patient dosed in trial with DermaVir patch for HIV

Rosuvastatin trial shows dramatic reduction in hidden heart disease

Phosphagenics' diclofenac enters trial phase in humans

Analyses of Merck's HIV vaccine 'Step' study

NicOx's Naproxcinod shows highly significant reduction in daytime blood pressure versus Naproxen

Raptor Pharmaceuticals announces positive results for Convivia program

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News